Acadia Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
State Street Corporation has updated its beneficial ownership filing for Acadia Pharmaceuticals Inc., reporting a significant holding of common stock.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of over 8.78 million shares, representing 5.15% of Acadia Pharmaceuticals Inc.'s common stock.
NASDAQ
The Vanguard Group has reported 0% beneficial ownership in ACADIA Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.
NASDAQ
RTW Investments and Roderick Wong reported a reduced beneficial ownership of 4.2% in Acadia Pharmaceuticals Inc. common stock.
NASDAQ
Investment firm RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a beneficial ownership of 5.2% in Acadia Pharmaceuticals Inc., totaling 8,705,501 shares.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, revealing a significant 11.9% beneficial ownership stake in Acadia Pharmaceuticals Inc. as of January 31, 2025.